Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vestronidase alfa in MPS 7
NCT02230566Phase 3Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Dec 2014
- Primary completion
- May 2016
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vestronidase alfa in mucopolysaccharidosis type VII (4 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Urinary Glycosaminoglycan Dermatan Sulfate at 24 weeks. Started Dec 2014; status: completed.
02
Drugs
vestronidase alfa
03
Conditions
mucopolysaccharidosis type VII
Beyond the preview
Go deeper on NCT02230566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02230566.